HC Wainwright Reiterates Neutral Rating for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 42.86% from the company’s current price.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Inovio Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $12.40.

Inovio Pharmaceuticals Trading Down 0.5 %

Inovio Pharmaceuticals stock opened at $2.10 on Wednesday. Inovio Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $14.75. The stock has a market cap of $54.81 million, a price-to-earnings ratio of -1.00 and a beta of 0.92. The company’s 50-day moving average price is $2.05 and its two-hundred day moving average price is $3.77.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Inovio Pharmaceuticals by 6.7% during the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares during the last quarter. Barclays PLC boosted its position in shares of Inovio Pharmaceuticals by 282.6% during the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 25,116 shares in the last quarter. FMR LLC lifted its stake in Inovio Pharmaceuticals by 370.1% during the third quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 21,462 shares during the period. State Street Corp boosted its holdings in Inovio Pharmaceuticals by 11.7% during the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after purchasing an additional 51,414 shares in the last quarter. Finally, Green Alpha Advisors LLC raised its holdings in shares of Inovio Pharmaceuticals by 103.2% in the 4th quarter. Green Alpha Advisors LLC now owns 65,446 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 33,232 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.